Market Brief: Global Market For Implantable Defibrillators Will Reach $10Bn By 2023
The global market for implantable cardioverter defibrillators (ICDs) is expected to reach $10bn by 2023, a CAGR of 4.4%, driven by the rising prevalence of heart disease worldwide. This market is dominated by three players, Abbott, Boston Scientific and Medtronic, which continue to innovate. Cost of ICDs and surgical implantation remain barriers to wider adoption, but access to emerging markets is expected to drive sales.
You may also be interested in...
The pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.
In a 28 March FAQ document, the US agency cautions manufacturers on the 3D printing of medical devices to address the shortage of ventilators and other medical supplies during the coronavirus pandemic.